Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR7 | P34969 | 12/20 | 0.65 |
| ▸ | HTR1A | P08908 | 3/20 | 0.62 |
| ▸ | LMNA | P02545 | 2/20 | 0.60 |
| ▸ | P2RX7 | Q99572 | 4/20 | 0.56 |
| ▸ | DRD2 | P14416 | 2/20 | 0.56 |
| ▸ | HTR2A | P28223 | 2/20 | 0.56 |
| ▸ | MEN1 | O00255 | 1/20 | 0.56 |
| ▸ | MLNR | O43193 | 1/20 | 0.56 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.56 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.56 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.56 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.56 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.56 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.56 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.56 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.56 |
| ▸ | PKM | P14618 | 1/20 | 0.56 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.56 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.56 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6844258 | 0.84 | HTR7 (0.67) | HTR7HTR1ALMNAP2RX7DRD2 | |
| SCHEMBL6843577 | 0.81 | HTR7 (0.69) | HTR7HTR1ALMNAP2RX7DRD2 | |
| SCHEMBL6843589 | 0.80 | HTR7 (0.64) | HTR7HTR1ALMNAP2RX7DRD2 | |
| SCHEMBL8136027 | 0.79 | HTR7 (0.72) | HTR7HTR1ALMNAP2RX7 | |
| SCHEMBL6839185 | 0.79 | HTR7 (0.65) | HTR7HTR1ALMNAP2RX7DRD2 | |
| SCHEMBL27031071 | 0.78 | HTR7 (0.70) | HTR7HTR1ALMNAP2RX7DRD2 | |
| SCHEMBL11200811 | 0.78 | HTR7 (0.75) | HTR7HTR1ALMNAP2RX7DRD2 | |
| SCHEMBL21751214 | 0.78 | ADRB2 (0.58) | OPRM1OPRK1 | |
| SCHEMBL29424028 | 0.78 | ADRB2 (0.58) | OPRM1OPRK1 | |
| SCHEMBL6844231 | 0.78 | HTR7 (0.61) | HTR7HTR1ALMNAP2RX7DRD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040116443-A1 | Dopamine D4 ligands for the treatment of novelty-seeking disorders | PFIZER INC | 2004-06-17 | — | — | US | claimed |
| US-20030158208-A1 | Dopamine D4 ligands for the treatment of novelty-seeking disorders | PFIZER INC. | 2003-08-21 | — | — | US | claimed |
| US-20020049209-A1 | Dopamine D4 ligands for the treatment of novelty-seeking disorders | PFIZER INC. | 2002-04-25 | — | — | US | claimed |
| EP-1177792-A2 | Dopamine D4 Ligands for the treatment of novelty-seeking disorders | Pfizer Products Inc. (US) | 2002-02-06 | — | — | EP | claimed |
| EP-0765320-B1 | BENZIMIDAZOLONE DERIVATIVES WITH CENTRAL DOPAMINERGIC ACTIVITY | PFIZER (US) | 2001-10-10 | — | — | EP | claimed |
| EP-0765320-A1 | BENZIMIDAZOLONE DERIVATIVES WITH CENTRAL DOPAMINERGIC ACTIVITY | PFIZER INC. (US) | 1997-04-02 | — | — | EP | claimed |
| WO-1995034555-A1 | BENZIMIDAZOLONE DERIVATIVES WITH CENTRAL DOPAMINERGIC ACTIVITY | PFIZER INC. (US) | 1995-12-21 | — | — | WO | claimed |
| US-20040116443-A1 | Dopamine D4 ligands for the treatment of novelty-seeking disorders | PFIZER INC | 2004-06-17 | — | — | US | disclosed |
| US-20030158208-A1 | Dopamine D4 ligands for the treatment of novelty-seeking disorders | PFIZER INC. | 2003-08-21 | — | — | US | disclosed |
| US-6548502-B2 | Preventing disorder selected from pathological gambling, attention deficit disorder with hyperactivity disorder, substance addiction such as drug and alcohol and sex in a mammals by administering pyrido(1,2-a) pyrazine derivatives | PFIZER INC | 2003-04-15 | — | — | US | disclosed |
| US-20020049209-A1 | Dopamine D4 ligands for the treatment of novelty-seeking disorders | PFIZER INC. | 2002-04-25 | — | — | US | disclosed |
| EP-1177792-A2 | Dopamine D4 Ligands for the treatment of novelty-seeking disorders | Pfizer Products Inc. (US) | 2002-02-06 | — | — | EP | disclosed |
| EP-0765320-B1 | BENZIMIDAZOLONE DERIVATIVES WITH CENTRAL DOPAMINERGIC ACTIVITY | PFIZER (US) | 2001-10-10 | — | — | EP | disclosed |
| EP-0765320-A1 | BENZIMIDAZOLONE DERIVATIVES WITH CENTRAL DOPAMINERGIC ACTIVITY | PFIZER INC. (US) | 1997-04-02 | — | — | EP | disclosed |
| WO-1995034555-A1 | BENZIMIDAZOLONE DERIVATIVES WITH CENTRAL DOPAMINERGIC ACTIVITY | PFIZER INC. (US) | 1995-12-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020049209-A1 | Dopamine D4 ligands for the treatment of novelty-seeking disorders | SLC6A3, DRD4, DRD2 | HTR7 152/4885HTR1A 85/4885LMNA 4884/4885 |
| US-20030158208-A1 | Dopamine D4 ligands for the treatment of novelty-seeking disorders | SLC6A3, DRD4, DRD2 | HTR7 152/4885HTR1A 85/4885LMNA 4884/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.